KOPRAN. share price has plunged 6% and is presently trading at Rs 211.4.
Meanwhile, the BSE HEALTHCARE index is at 42,657.3 (up 1.3%).
Among the top losers in the BSE HEALTHCARE index today are CAPLIN POINT (down 1.4%) and SUVEN PHARMACEUTICALS (down 1.1%).
Divis Laboratories (up 3.1%) and GRANULES INDIA (up 3.0%) are among the top gainers today.
Over the last one year, KOPRAN. has moved down from Rs 244.7 to Rs 211.4, registering a loss of Rs 33.3 (down 13.6%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,951.5 to 42,657.3, registering a gain of 47.3% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 171.6%), SUVEN PHARMACEUTICALS (up 122.7%) and Glenmark Pharma (up 101.1%).
The BSE Sensex is at 78,202.1 (up 1.1%).
The top gainers among the BSE Sensex today are M&M (up 4.6%) and Tech Mahindra (up 3.4%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.
In the meantime, NSE Nifty is at 23,726.3 (up 1.2%). M&M and Tata Motors are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,675.9 to 78,202.1, registering a gain of 12,526.2 points (up 19.1%).
KOPRAN. net profit fell 46.4% YoY to Rs 74 million for the quarter ended September 2024, compared to a profit of Rs 138 million a year ago. Net sales declined 0.7% to Rs 1,516 million during the period as against Rs 1,526 million in July-September 2023.
For the year ended March 2024, KOPRAN. reported 87.1% increase in net profit to Rs 510 million compared to net profit of Rs 272 million during FY23. Revenue of the company grew 11.5% to Rs 6,146 million during FY24.
The current Price to earnings ratio of KOPRAN., based on rolling 12 month earnings, stands at 19.3.
Equitymaster requests your view! Post a comment on "KOPRAN. Plunges 6%; BSE HEALTHCARE Index Up 1.3%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!